Related references
Note: Only part of the references are listed.ATRA modulates mechanical activation of TGF-β by pancreatic stellate cells
Muge Sarper et al.
SCIENTIFIC REPORTS (2016)
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
Yutaka Fujiwara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
G. Giaccone et al.
EUROPEAN JOURNAL OF CANCER (2015)
Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
Armin Maier et al.
CELLULAR ONCOLOGY (2015)
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
Jordi Rodon et al.
INVESTIGATIONAL NEW DRUGS (2015)
Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model
Ivelina Gueorguieva et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition
Chul-Yong Park et al.
CANCER LETTERS (2014)
Effective Chemoimmunotherapy with Anti-TGFβ Antibody and Cyclophosphamide in a Mouse Model of Breast Cancer
Xin Chen et al.
PLOS ONE (2014)
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
John C. Morris et al.
PLOS ONE (2014)
Peripheral TGF-β1 Signaling Is a Critical Event in Bone Cancer-Induced Hyperalgesia in Rodents
Qian Xu et al.
JOURNAL OF NEUROSCIENCE (2013)
Transforming Growth Factor β Neutralization Ameliorates Pre-Existing Hepatic Fibrosis and Reduces Cholangiocarcinoma in Thioacetamide-Treated Rats
Hong Ling et al.
PLOS ONE (2013)
TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment
Yoko Tabe et al.
PLOS ONE (2013)
Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
Francesco Dituri et al.
PLOS ONE (2013)
Immunological efects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
James P. Stevenson et al.
ONCOIMMUNOLOGY (2013)
Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth
Xinhai Wan et al.
BONE (2012)
Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host
Z. Zhang et al.
CANCER GENE THERAPY (2012)
Systemic Delivery of Oncolytic Adenoviruses Targeting Transforming Growth Factor-β Inhibits Established Bone Metastasis in a Prostate Cancer Mouse Model
Zebin Hu et al.
HUMAN GENE THERAPY (2012)
Complexities of TGF-β Targeted Cancer Therapy
Erin C. Connolly et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Increased TGF-β1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2/3 signaling
Fayth L. Miles et al.
PROSTATE (2012)
Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study
Emilia Fransvea et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
TGF-beta-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases
Khalid S. Mohammad et al.
CANCER RESEARCH (2011)
Blockade of TGF-β Signaling by the TGFβR-I Kinase Inhibitor LY2109761 Enhances Radiation Response and Prolongs Survival in Glioblastoma
Mengxian Zhang et al.
CANCER RESEARCH (2011)
Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
Karl-Hermann Schlingensiepen et al.
CANCER SCIENCE (2011)
TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo
Fanny Bouquet et al.
CLINICAL CANCER RESEARCH (2011)
Oncolytic Adenovirus Expressing Soluble TGFβ Receptor II-Fc-mediated Inhibition of Established Bone Metastases: A Safe and Effective Systemic Therapeutic Approach for Breast Cancer
Zebin Hu et al.
MOLECULAR THERAPY (2011)
Targeted therapy for high-grade glioma with the TGF-beta 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
U. Bogdahn et al.
NEURO-ONCOLOGY (2011)
Trimodal Glioblastoma Treatment Consisting of Concurrent Radiotherapy, Temozolomide, and the Novel TGF-β Receptor I Kinase Inhibitor LY2109761
Mengxian Zhang et al.
NEOPLASIA (2011)
Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival
Sana Intidhar Labidi et al.
ANNALS OF HEMATOLOGY (2010)
Inhibitory effect of a TGFβ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells
O. Shinto et al.
BRITISH JOURNAL OF CANCER (2010)
The type III TGF-β receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-β signaling
Jason D. Lee et al.
CARCINOGENESIS (2010)
Targeting the transforming growth factor-beta signaling pathway in human cancer
Nagathihalli S. Nagaraj et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Antimetastatic Role of Smad4 Signaling in Colorectal Cancer
Bixiang Zhang et al.
GASTROENTEROLOGY (2010)
Targeting the Transforming Growth Factor-β pathway inhibits human basal-like breast cancer metastasis
Vidya Ganapathy et al.
MOLECULAR CANCER (2010)
Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis
M. Petersen et al.
ONCOGENE (2010)
Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity
Hiroaki Tanaka et al.
ONCOLOGY REPORTS (2010)
TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth
Kyoko Takeuchi et al.
PLOS ONE (2010)
Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients
J. Nemunaitis et al.
CANCER GENE THERAPY (2009)
Targeting transforming growth factor-β signaling in liver metastasis of colon cancer
Bixiang Zhang et al.
CANCER LETTERS (2009)
Inhibition of Transforming Growth Factor β Receptor I Kinase Blocks Hepatocellular Carcinoma Growth Through Neo-angiogenesis Regulation
Antonio Mazzocca et al.
HEPATOLOGY (2009)
TGF-β effects on airway smooth muscle cell proliferation, VEGF release and signal transduction pathways
Joo Hwa Shin et al.
RESPIROLOGY (2009)
Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS
Li Zhou et al.
BLOOD (2008)
An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments
Jeong-Seok Nam et al.
CANCER RESEARCH (2008)
TβRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity
Elizabeth C. Finger et al.
CARCINOGENESIS (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice
Lorea Bueno et al.
EUROPEAN JOURNAL OF CANCER (2008)
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy
Shahrokh F. Shariat et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy
Min Zhang et al.
JOURNAL OF IMMUNOLOGY (2008)
Increased TGF-beta1 protein expression in patients with advanced colorectal cancer
Marcus Langenskiod et al.
JOURNAL OF SURGICAL ONCOLOGY (2008)
Effect of IN-1130, a Small Molecule Inhibitor of Transforming Growth Factor-β Type I Receptor/Activin Receptor-Like Kinase-5, on Prostate Cancer Cells
Geun Taek Lee et al.
JOURNAL OF UROLOGY (2008)
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
Davide Melisi et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
Anne-Pierre Morel et al.
PLOS ONE (2008)
Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice
Shan Lu et al.
CLINICAL CANCER RESEARCH (2007)
Inhibition of transforming growth factor β signaling reduces pancreatic adenocarcinoma growth and invasiveness
Nicholas J. Gaspar et al.
MOLECULAR PHARMACOLOGY (2007)
Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression
Swati Biswas et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene
Alejandra Bruna et al.
CANCER CELL (2007)
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line
Shogo Ehata et al.
CANCER SCIENCE (2007)
The type III TGF-beta receptor suppresses breast cancer progression
Mei Dong et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Inhibition of TGF-beta 2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I/II studies
Peter Hau et al.
OLIGONUCLEOTIDES (2007)
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
John Nemunaitis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Overexpression of TGF-β1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis
Burkhard H. A. von Rahden et al.
MOLECULAR CARCINOGENESIS (2006)
Inhibition of transforming growth factor-β1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA
Bryan M. Zhao et al.
MOLECULAR BIOLOGY OF THE CELL (2006)
Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor
Julien C. Marie et al.
IMMUNITY (2006)
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo
Rongrong Ge et al.
CLINICAL CANCER RESEARCH (2006)
Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations
WM Grady et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
KH Schlingensiepen et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner
F Ghiringhelli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Smad7 induces turnorigenicity by blocking TGF-β-induced growth inhibition and apoptosis
SK Halder et al.
EXPERIMENTAL CELL RESEARCH (2005)
Selective inhibition of TGF-β responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP
QQ Cui et al.
ONCOGENE (2005)
Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: Toxicology and safety
R Schlingensiepen et al.
OLIGONUCLEOTIDES (2005)
Soluble type II transforming growth factor-β receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2004)
Transforming growth factor β receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment
T Hayashi et al.
CLINICAL CANCER RESEARCH (2004)
SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo
M Uhl et al.
CANCER RESEARCH (2004)
Targeting the TGFβ signaling network in human neoplasia
N Dumont et al.
CANCER CELL (2003)
Tumor-derived TGF-β reduces the efficacy of dendritic cell/tumor fusion vaccine
JY Kao et al.
JOURNAL OF IMMUNOLOGY (2003)
TGF-β:: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression
WJ Chen et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
Reversal of tumor-induced immunosuppression by TGF-β inhibitors
S Wojtowicz-Praga
INVESTIGATIONAL NEW DRUGS (2003)
Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter
SQ Wu et al.
ONCOGENE (2003)
Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-β receptor type II
WL Zhao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
TGF-β receptor-activated p38 MAP kinase mediates smad-independent TGF-β responses
L Yu et al.
EMBO JOURNAL (2002)
Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity:: SB-431542
NJ Laping et al.
MOLECULAR PHARMACOLOGY (2002)
Balancing the activation state of the endothelium via two distinct TGF-β type I receptors
MJ Goumans et al.
EMBO JOURNAL (2002)
TGF-β signaling in tumor suppression and cancer progression
R Derynck et al.
NATURE GENETICS (2001)
TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b
J Seoane et al.
NATURE CELL BIOLOGY (2001)
Transforming growth factor-beta 1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism
NA Bhowmick et al.
MOLECULAR BIOLOGY OF THE CELL (2001)
Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration
AV Bakin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Recombinant soluble transforming growth factor β type II receptor ameliorates radiation enteropathy in mice
H Zheng et al.
GASTROENTEROLOGY (2000)
Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins
A Lasorella et al.
NATURE (2000)
BF-1 interferes with transforming growth factor β signaling by associating with Smad partners
CL Dou et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis
I Schwarte-Waldhoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
